Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Top Cited Papers
Open Access
Abstract
Understanding immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for improving diagnostics and vaccines and for assessing the likely future course of the COVID-19 pandemic. We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥6 months after infection. Immunoglobulin G (IgG) to the spike protein was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month after symptom onset. SARS-CoV-2–specific CD4+ T cells and CD8+ T cells declined with a half-life of 3 to 5 months. By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.
Funding Information
  • National Institutes of Health (Nr. 75N9301900065)
  • National Institute of Allergy and Infectious Diseases (AI142742)
  • National Institute of Allergy and Infectious Diseases (AI135078)
  • National Institute of Allergy and Infectious Diseases (HHSN272201400008C)
  • National Institute of Allergy and Infectious Diseases (75N93019C00051)
  • National Institute of Allergy and Infectious Diseases (AI007036)
  • National Institute of Allergy and Infectious Diseases (U01 AI141995)
  • Bill and Melinda Gates Foundation (INV-006133)
  • Wellcome (INV-006133)
  • Mastercard Incorporated (INV-006133)
  • National Institute of Allergy and Infectious Diseases (AI141995-03)
  • National Institute of Allergy and Infectious Diseases (U01 CA260541-01)
  • JPB Foundation
  • Open Philanthropy Project (2020-215611)
  • Steven and Alexandra Cohen Foundation
  • John and Mary Tu Foundation
  • National Institute of Allergy and Infectious Diseases (AI007384)